PTK787

DRUG5 trials

Sponsors

University of Michigan Rogel Cancer Center, Novartis, Hoosier Cancer Research Network, Dana-Farber Cancer Institute, David Rizzieri, MD

Conditions

Breast CancerCervical CancerEndometrial CancerFallopian Tube CancerLymphoma, Large-Cell, DiffuseOvarian CancerPeritoneal CancerProstate Cancer

Phase 1

Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

CompletedNCT00138632

NovartisWet Age-Related Macular Degeneration

Start: 2005-09-30Updated: 2008-11-14

PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer

TerminatedNCT00216047

Hoosier Cancer Research NetworkBreast Cancer

Start: 2005-01-31End: 2006-08-31Updated: 2015-12-09

Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients

CompletedNCT00268918

Dana-Farber Cancer InstituteBreast Cancer, Cervical Cancer, Endometrial Cancer +3

Start: 2005-09-30End: 2011-01-31Updated: 2018-07-27

Phase 2

Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer

CompletedNCT00134355

University of Michigan Rogel Cancer CenterProstate Cancer

Start: 2005-07-31End: 2007-03-31Updated: 2015-01-19

PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma

TerminatedNCT00511043

David Rizzieri, MDLymphoma, Large-Cell, Diffuse

Start: 2005-11-30End: 2010-06-30Updated: 2014-12-09